- Datum02.04.2025
- UhrzeitLäuft gerade
- Veranstalter
XTB
Kein Moderator verfügbar
uniQure N.V. Aktie
Verkaufen
Kaufen
uniQure N.V. Chart
uniQure N.V. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-6,60 %
Intraday
-27,40 %
1 Woche
-24,64 %
1 Monat
-43,88 %
Seit Jahresbeginn
99,00 %
1 Jahr
-49,05 %
3 Jahre
-78,90 %
5 Jahre
-56,65 %
10 Jahre
Wikifolio
Passender Service zu uniQure N.V.
Webinar zu uniQure N.V.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)3,730-19,180
- Jahrestief / Hoch ($)9,380-19,180
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von uniQure N.V.
Keine Dividenden verfügbar
Termine von uniQure N.V.
- Mai13uniQure N.V.Q1 2025 Earnings Release
- Jul31uniQure N.V.Q2 2025 Earnings Release
Beschreibung
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
